MassMutual Private Wealth & Trust’s Esperion Therapeutics ESPR Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.48K	Sell	2,050 -450	-18%	-$1.26K	﹤0.01%	1587
2026 Q1	$6.85K	Buy	2,500 +1,268	+103%	+$4.01K	﹤0.01%	1533
2025 Q4	$4.56K	Buy	1,232 +492	+66%	+$1.59K	﹤0.01%	1716
2025 Q3	$1.96K	Buy	+740	New	+$1.43K	﹤0.01%	1992
2025 Q2	–	Sell	-1,394	Closed	-$2.01K	–	2397
2025 Q1	$2.01K	Buy	+1,394	New	+$2.57K	﹤0.01%	1914
2022 Q4	–	Sell	-40	Closed	–	–	1700
2022 Q3	$0	Buy	+40	New	+$275	﹤0.01%	1669

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

MassMutual Private Wealth & Trust's ESPR Position: Q2 2026 in Review

MassMutual Private Wealth & Trust reduced its Esperion Therapeutics (ESPR) stake by 18% in Q2 2026, selling an estimated $1.26K and leaving 2,050 shares worth $6.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1587.

MassMutual Private Wealth & Trust first reported a position in ESPR in Q3 2022 and has held it in 6 quarters since. The position peaked at $6.85K in Q1 2026. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

MassMutual Private Wealth & Trust held 2,050 shares of Esperion Therapeutics worth $6.48K as of Q2 2026.
MassMutual Private Wealth & Trust sold 450 Esperion Therapeutics shares in Q2 2026, an estimated $1.26K.
Esperion Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #1587 holding.
MassMutual Private Wealth & Trust first reported a position in Esperion Therapeutics in Q3 2022 and has held it in 6 quarters since.
MassMutual Private Wealth & Trust's Esperion Therapeutics position peaked at $6.85K in Q1 2026.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.